| Literature DB >> 28255235 |
Jae-Beom Lee1, Yun-Seok Choi2, Woo-Baek Chung2, Ami Kwon2, Chul-Soo Park2, Man-Young Lee2.
Abstract
PURPOSE: High coronary calcium score (CCS) and post-procedural cardiac enzyme may be related with poor outcomes in patients with coronary stent implantation.Entities:
Keywords: calcium; coronary restenosis; creatine kinase; drug-eluting stents
Mesh:
Substances:
Year: 2017 PMID: 28255235 PMCID: PMC5322937 DOI: 10.2147/CIA.S125592
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Baseline clinical characteristics in groups with and without TLR
| Group 1: | Group 2: | ||
|---|---|---|---|
| Male sex | 592 (56.2) | 95 (58.6) | 0.13 |
| Age (years) | 63.4±10.1 | 62.1±9.0 | 0.07 |
| BMI (kg/m2) | 25.41±4.00 | 24.5±3.2 | 0.06 |
| DM | 202 (22.1) | 34 (39.0) | 0.11 |
| HBP | 402 (44.1) | 86 (72.8) | 0.12 |
| Smoking | 167 (18.3) | 43 (26.5) | 0.40 |
| FBG (mg/dL) | 123.7±43.9 | 121.6±40.2 | 0.40 |
| HbA1c (%) | 6.4±1.1 | 6.4±1.2 | 0.53 |
| Creatinine (mg/dL) | 1.07±0.6 | 1.1±0.3 | 0.20 |
| CRP (IU) | 8.6±11.8 | 9.3±17.4 | 0.57 |
| TC (mg/dL) | 170.3±43.1 | 165.5±44.2 | 0.91 |
| TG (mg/dL) | 136.48±80.07 | 144.3±97.0 | 0.12 |
| HDL (mg/dL) | 41.9±11.6 | 42.3±10.3 | 0.41 |
| LDL (mg/dL) | 101.9±39.2 | 95.3±32.5 | 0.60 |
| Pro-BNP (pg/mL) | 424.9±1.6 | 423.7±1.2 | 0.83 |
| Calcium score | 345.8±51.05 | 1,102.4±743.7 | 0.04 |
| Post-procedural CK-MB elevation | 157 (17.2) | 135 (83.3) | 0.02 |
| Stent type (lesion) | |||
| PES | 322 (35.3) | 82 (37.3) | 0.04 |
| SES | 816 (69.6) | 114 (51.8) | 0.09 |
| EES | 68 (5.2) | 9 (4.1) | 0.23 |
| ZES | 91 (7.1) | 15 (6.8) | 0.45 |
| Stent diameter (mm) | 3.20±0.6 | 3.18±1.9 | 0.84 |
| Stent length (mm) | 32.4±11.4 | 34.8±17.2 | 0.07 |
| True bifurcation | 270 (29.6) | 42 (25.9) | 0.24 |
| AHA/ACC lesion B2/C | 188 (20.6) | 32 (19.8) | 0.81 |
| Side branch occlusion (≥2.5 mm) | 19 (2.1) | 4 (2.2) | 0.20 |
Notes:
P<0.05.
Patient number (>2 times elevation of the upper normal limit). Data presented as mean ± standard deviation or n (%).
Abbreviations: BMI, body mass index; CK-MB, creatine kinase MB form; CRP, C-reactive protein; DM, diabetes mellitus; EES, everolimus eluting stent; FBG, fasting blood glucose; HBP, hypertension; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PES, paclitaxel eluting stent; pro-BNP, pro B-type natriuretic peptide; SES, sirolimus eluting stent; stent type, coronary stent type; TC, total cholesterol; TG, triglyceride; TLR, target lesion revascularization; ZES, zotarolimus eluting stent; AHA, American College of Cardiology; ACC, American Heart Association.
Logistic regression analysis of the influencing factors for prediction of TLR in lesions
| Factor | Univariate analysis
| Multivariate analysis
| ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Sex | 0.89 (0.67–1.19) | 0.37 | – | – |
| Age | 1.18 (0.99–1.32) | 0.37 | 1.13 (0.94–1.19) | 0.49 |
| BMI | 0.95 (0.90–0.99) | 0.02 | 0.92 (0.35–1.24) | 0.48 |
| DM | 1.27 (0.87–1.69) | 0.13 | 0.84 (0.18–2.22) | 0.39 |
| HBP | 1.42 (1.03–2.06) | 0.02 | 2.11 (0.78–11.9) | 0.16 |
| Smoking | 0.83 (0.59–1.19) | 0.24 | – | – |
| FBG | 0.99 (0.99–1.00) | 0.47 | ||
| HbA1c | 1.10 (0.89–1.12) | 0.91 | – | – |
| Creatinine | 1.20 (0.90–1.30) | 0.32 | – | – |
| hs-CRP | 1.45 (0.49–1.95) | 0.88 | – | – |
| TC | 1.10 (0.99–1.20) | 0.75 | – | – |
| TG | 1.23 (0.79–1.24) | 0.21 | – | – |
| HDL | 0.99 (0.98–1.01) | 0.60 | – | – |
| LDL | 0.99 (0.99–1.02) | 0.50 | – | – |
| Stent type | 0.04 | – | 0.73 | |
| PES | 0.54 (0.40–0.70) | <0.01 | 0.65 (0.19–2.17) | 0.41 |
| SES | 0.23 (0.05–0.61) | 0.06 | 1.00 (0.98–1.13) | 0.91 |
| EES | 0.71 (0.38–1.21) | 0.24 | 2.04 (0.42–10.09) | 0.36 |
| ZES | 0.97 (0.12–1.28) | 0.13 | 3.06 (0.14–67.11) | 0.49 |
| Stent diameter | 1.017 (0.86–1.19) | 0.84 | – | – |
| Stent length | 1.028 (1.01–1.03) | 0.11 | 1.05 (1.02–1.09) | 0.22 |
| Calcium score | 1.41 (1.20–1.51) | 0.01 | 1.30 (1.19–1.48) | 0.01 |
| CK-MB elevation | 1.60 (1.33–1.70) | 0.02 | 1.45 (1.28–1.51) | 0.02 |
Notes:
P<0.05.
More than two times elevation of the upper normal limit.
Abbreviations: BMI, body mass index; CK-MB, creatine kinase MB; CI, confidence interval; DM, diabetes mellitus; EES, everolimus eluting stent; FBG, fasting blood glucose; HBP, hypertension; HDL, high-density lipoprotein; hs-CRP, high sensitive C-reactive protein; LDL, low-density lipoprotein; OR, odds ratio; PES, paclitaxel eluting stent; SES, sirolimus eluting stent; stent type, coronary stent type; TC, total cholesterol; TG, triglyceride; TLR, target lesion revascularization; ZES, zotarolimus eluting stent.
Figure 1On the receiver operating curve, the calcium score was a significant predictor for TLR. A calcium score of 800 has a sensitivity of 60% and specificity of 85%.
Abbreviations: AUC, area under curve; TLR, target lesion revascularization.
Incidence of target lesion revascularization according to coronary calcium score and post-procedural CK-MB elevation
| CK-MB elevation | Group I, CCS <300
| Group II, 300≤ CCS ≤800
| Group III, CCS >800
| |||
|---|---|---|---|---|---|---|
| TLR (−), | TLR (+), | TLR (−), | TLR (+), | TLR (−), | TLR (+), | |
| (−) | 356 (85.8) | 5 (1.2) | 224 (68.9) | 10 (3.0) | 173 (51.3) | 12 (3.5) |
| (+) | 40 (9.6) | 2 (0.4) | 46 (14.1) | 35 (10.7) | 71 (21.0) | 98 (29.0) |
Notes:
P<0.05 compared to Groups I and II.
Patient number (>2 times elevation of the upper normal limit). Data presented as n (%).
Abbreviations: CCS, coronary calcium score; CK-MB, creatine kinase MB form; TLR, target lesion revascularization.